A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Yiyin ZhangJin XuJie HuaJiang LiuChen LiangQingcai MengMiaoyan WeiBo ZhangXian-Jun YuSi ShiPublished in: Journal for immunotherapy of cancer (2019)
Our work highlighted PD-L2 as a promising immunotherapeutic target with prognostic value combined with complex tumor infiltrating cells in PDAC.